Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
| ▸ | F13A1 | P00488 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | TGM1 | P22735 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL540519 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL1841984 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL5368396 | 0.92 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL6128832 | 0.92 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL2440282 | 0.92 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL77639 | 0.91 | SMN1; SMN2 (0.76) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL16903351 | 0.90 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL6873826 | 0.90 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL30599923 | 0.90 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL18084804 | 0.89 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141412-B2 | Process for preparing optically active 3-hydroxypyrrolidine derivatives by enzymatic hydroxylation | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2006-11-28 | — | — | US | claimed |
| EP-1131460-B1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 3-HYDROXY-PYRROLIDINE DERIVATIVEES BY ENZYMATIC HYDROXYLATION | EIDGENOESS TECH HOCHSCHULE (CH) | 2004-10-06 | — | — | EP | claimed |
| US-20040029237-A1 | Process for preparing n-substituted 4-hydroxypiperidines by enzymatic hudroxylation | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2004-02-12 | — | — | US | claimed |
| US-20030219883-A1 | Process for preparing optically active 3-hydroxypyrrolidine derivatives by enzymatic hydroxylation | LI ZHI (CH) | 2003-11-27 | — | — | US | claimed |
| EP-1319085-A1 | PROCESS FOR PREPARING N-SUBSTITUTED 4-HYDROXYPIPERIDINES BY ENZYMATIC HYDROXYLATION | Eidgenössische Technische Hochschule Zürich (CH) | 2003-06-18 | — | — | EP | claimed |
| US-20020106763-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 3-HYDROXY-PYRROLIDINE DERIVATIVES BY ENZYMATIC HYDROXYLATION | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2002-08-08 | — | — | US | claimed |
| WO-2002022845-A1 | PROCESS FOR PREPARING N-SUBSTITUTED 4-HYDROXYPIPERIDINES BY ENZYMATIC HYDROXYLATION | Eidgenössische Technische Hochschule Zürich (CH) | 2002-03-21 | — | — | WO | claimed |
| EP-1188837-A1 | Process for preparing N-substituted 4-hydroxypiperidines by enzymatic hydroxylation | Eidgenössische Technische Hochschule Zürich (CH) | 2002-03-20 | — | — | EP | claimed |
| EP-1131460-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 3-HYDROXY-PYRROLIDINE DERIVATIVEES BY ENZYMATIC HYDROXYLATION | Eidgenössische Technische Hochschule Zürich (CH) | 2001-09-12 | — | — | EP | claimed |
| WO-2000029606-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE-3-HYDROXY-PYRROLIDINE DERIVATIVES BY ENZYMATIC HYDROXYLATION | Eidgenössische Technische Hochschule Zürich (CH) | 2000-05-25 | — | — | WO | claimed |
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-12 | — | — | US | disclosed |
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2025-11-13 | — | — | US | disclosed |
| US-20250340565-A1 | CD73 INHIBITOR COMPOUNDS | ADORX THERAPEUTICS LTD (GB) | 2025-11-06 | — | — | US | disclosed |
| WO-2025229549-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PARG | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2025-11-06 | — | — | WO | disclosed |
| EP-4587446-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2025-07-23 | — | — | EP | disclosed |
| WO-1991008206-A1 | N-ACYL-SUBSTITUTED AZACYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS | DR. LO. ZAMBELETTI S.P.A. (IT) | 1991-06-13 | — | — | WO | disclosed |
| US-4952600-A | TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMERICAN CYANAMID COMPANY (US) | 1990-08-28 | — | — | US | disclosed |
| EP-0381984-A1 | 3- or 4-substituted oxotremorine derivatives | AMERICAN CYANAMID COMPANY (US) | 1990-08-16 | — | — | EP | disclosed |
| US-4937235-A | Anticholinergic agents | AMERICAN CYANAMID COMPANY (US) | 1990-06-26 | — | — | US | disclosed |
| EP-0367110-A1 | 1,4-diazepine derivative and its pharmaceutical use | Eisai Co., Ltd. (JP) | 1990-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | SORT1, SCARB1, LAMP1 | SMN1; SMN2 3525/4885NPC1 110/4885RAB9A 977/4885 |
| US-20250340565-A1 | CD73 INHIBITOR COMPOUNDS | ENTPD5, ENTPD1, NT5E | SMN1; SMN2 3356/4885NPC1 1842/4885RAB9A 1996/4885 |
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CSNK1A1, CSNK2A3, CSNK1G1 | SMN1; SMN2 2510/4885NPC1 2876/4885RAB9A 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.